

**Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials**

David M.G. Halpin<sup>1</sup>, Claus F. Vogelmeier<sup>2</sup>, Karen Mezzi<sup>3</sup>, Pritam Gupta<sup>4</sup>, Konstantinos Kostikas<sup>5</sup>, Jadwiga A. Wedzicha<sup>6</sup>

<sup>1</sup>University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom; <sup>2</sup>University Medical Centre Giessen and Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany; <sup>3</sup>Novartis Pharma AG, Basel, Switzerland; <sup>4</sup>Novartis Healthcare Pvt. Ltd., Hyderabad, India; <sup>5</sup>Respiratory Medicine Department, University of Ioannina, Greece; <sup>6</sup>National Heart and Lung Institute, Imperial College London, London, United Kingdom

**Corresponding author**

Prof. David MG Halpin

Consultant Physician & Honorary Professor

University of Exeter Medical School

College of Medicine and Health

University of Exeter

Exeter, UK

Tel +44 (0)1392 402133

Fax +44(0)1392 402828

**SUPPLEMENTARY FILE**

**Table S1. Key inclusion criteria and key exclusion criteria of patients included in the analysis**

ILLUMINATE study	LANTERN study	FLAME study
Key inclusion criteria:		
Men and women aged $\geq 40$ years	Men and women aged $\geq 40$ years	Men and women aged $\geq 40$ years
Smoking history of at least 10 pack-years	Smoking history of at least 10 pack-years	Smoking history of at least 10 pack-years
Post-bronchodilator FEV <sub>1</sub> between $\geq 40\%$ and $< 80\%$ of predicted normal	Post-bronchodilator FEV <sub>1</sub> between $\geq 30\%$ and $< 80\%$ of predicted normal	Post-bronchodilator FEV <sub>1</sub> between $\geq 25\%$ and $< 60\%$ of predicted normal
Post-bronchodilator FEV <sub>1</sub> /FVC ratio $< 0.70$	Post-bronchodilator FEV <sub>1</sub> /FVC ratio $< 0.70$	Post-bronchodilator FEV <sub>1</sub> /FVC ratio $< 0.70$
Symptomatic patients, according to daily electronic diary data, with a total score $\geq 1$ on at least 4 of the last 7 days during run-in period	mMRC grade $\geq 2$ at screening	mMRC grade $\geq 2$ at screening  History of $\geq 1$ COPD exacerbation in the previous year that required treatment with SCS and/or

antibiotics	
Key exclusion criteria:	
ILLUMINATE and LANTERN study	FLAME study
A history of a COPD exacerbation needing treatment with antibiotics, SCS, or hospitalisation in the year prior to screening	COPD exacerbation that required treatment with antibiotics and/or SCS and/or hospitalisation in the 6 weeks prior to screening
Any history of asthma	Any history of asthma
Blood eosinophil count $>600/\text{mm}^3$ at the start of run-in period	Blood eosinophil count $>600/\text{mm}^3$ at the start of run-in period
COPD, chronic obstructive pulmonary disease; FEV <sub>1</sub> , forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Obstructive Lung Disease; mMRC, modified Medical Research Council; SCS, systemic corticosteroid	